Martin A. Makary Net Worth

The estimated Net Worth of Martin A. Makary is at least $1.86 Million dollars as of 14 August 2023. Martin Makary owns over 20,000 units of Harrow Health stock worth over $1,861,650 and over the last 2 years Martin sold HROW stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Martin Makary HROW stock SEC Form 4 insiders trading

Martin has made over 2 trades of the Harrow Health stock since 2022, according to the Form 4 filled with the SEC. Most recently Martin bought 20,000 units of HROW stock worth $338,400 on 14 August 2023.

The largest trade Martin's ever made was buying 25,000 units of Harrow Health stock on 21 December 2022 worth over $334,250. On average, Martin trades about 9,000 units every 47 days since 2022. As of 14 August 2023 Martin still owns at least 45,000 units of Harrow Health stock.

You can see the complete history of Martin Makary stock trades at the bottom of the page.

What's Martin Makary's mailing address?

Martin's mailing address filed with the SEC is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205.

Insiders trading at Harrow Health

Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum, and Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.

What does Harrow Health do?

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Complete history of Martin Makary stock trades at Harrow Health

Harrow Health executives and stock owners

Harrow Health executives and other stock owners filed with the SEC include:

• Mark Baum,
  Chief Executive Officer, Director
• Andrew Boll,
  Chief Financial Officer, Corporate Secretary
• John Saharek,
  President of ImprimisRx
• Mark L. Baum J.D.,
  CEO & Chairman
• Andrew R. Boll C.F.A., C.M.A., CFA, CMA,
  CFO & Corp. Sec.
• John P. Saharek,
  Pres of ImprimisRx
• Richard Lindstrom,
  Director
• Robert Kammer,
  Independent Chairman of the Board
• Dr. Robert J. Kammer D.D.S.,
  Special Advisor
• R. Lawrence Van Horn,
  Independent Director
• Teresa Sparks,
  Independent Director
• Larry Dillaha,
  Chief Medical Officer
• Kim Barratt,
  Chief Talent Officer
• Dr. Larry M. Dillaha M.D.,
  Chief Medical Officer
• David Moufarrège,
  VP of Technology
• Jamie Webb,
  Director of Communications & Investor Relations
• Andrew Livingston,
  Chief Innovation Officer
• Dr. Dennis E Saadeh Pharm.D.,
  Chief of Formulation Strategy
• David Moufarrège,
  VP of Technology
• Lauren P Silvernail,
  Director
• Stephen G Austin,
  Director
• Anthony Principi,
  Director
• Management Inc. Opaleye,
  10% owner
• Perry J. Sternberg,
  Director
• Martin A. Makary,
  Director